skip to main content

H.R. 3537: Accelerating Access to Critical Therapies for ALS Act


To direct the Secretary of Health and Human Services to support research on, and expanded access to, investigational drugs for amyotrophic lateral sclerosis, and for other purposes.

Sponsor and status

Mike Quigley

Sponsor. Representative for Illinois's 5th congressional district. Democrat.

Read Text »
Last Updated: Dec 21, 2021
Length: 6 pages
Introduced
May 25, 2021
117th Congress (2021–2023)
Status

Enacted — Signed by the President on Dec 23, 2021

This bill was enacted after being signed by the President on December 23, 2021.

Law
Pub.L. 117-79
Cosponsors

331 Cosponsors (186 Democrats, 145 Republicans)

Source

Position statements

What legislators are saying

Congressman Higgins Announces Approval of the Accelerating Access to Critical Therapies for ALS Act
    — Rep. Brian Higgins [D-NY26] (Co-sponsor) on Dec 10, 2021

Congressman Griffiths Weekly E-Newsletter 8.13.21
    — Rep. Morgan Griffith [R-VA9] (Co-sponsor) on Aug 13, 2021

A Vote Against Congress, Not ALS: Rep. Roy’s statement on H.R. 3537
    — Rep. Chip Roy [R-TX21] on Dec 9, 2021

More statements at ProPublica Represent...

What stakeholders are saying

R Street Institute SpendingTracker.org estimates new spending due to H.R. 3537 will be negligible.

Incorporated legislation

This bill incorporates provisions from:

S. 1813: Accelerating Access to Critical Therapies for ALS Act

Introduced on May 25, 2021. 89% incorporated. (compare text)

History

May 25, 2021
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Nov 4, 2021
 
Considered by Health

A committee held a hearing or business meeting about the bill.

Nov 17, 2021
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Dec 3, 2021
 
Text Published

Updated bill text was published as of Preprint (Suspension).

Dec 8, 2021
 
Passed House (Senate next)

The bill was passed in a vote in the House. It goes to the Senate next.

Dec 8, 2021
 
Reported by House Committee on Energy and Commerce

A committee issued a report on the bill, which often provides helpful explanatory background on the issue addressed by the bill and the bill's intentions.

Dec 16, 2021
 
Passed Senate

The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill. The vote was by Voice Vote so no record of individual votes was made.

Dec 23, 2021
 
Enacted — Signed by the President

The President signed the bill and it became law.

H.R. 3537 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Bills numbers restart every two years. That means there are other bills with the number H.R. 3537. This is the one from the 117th Congress.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 3537 — 117th Congress: Accelerating Access to Critical Therapies for ALS Act.” www.GovTrack.us. 2021. July 1, 2022 <https://www.govtrack.us/congress/bills/117/hr3537>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.